Shattuck Labs, Inc.

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing monoclonal and bispecific Death Receptor 3 (DR3) blocking antibodies for inflammatory and immune-mediated diseases. The company leverages its expertise in protein engineering and tumor necrosis factor (TNF) receptor therapeutics. Its lead program, SL-325, is a high-affinity DR3 blocking monoclonal antibody. SL-325 is designed to more completely block the DR3/TL1A pathway compared to TL1A blocking antibodies. DR3 is the only known receptor for tumor necrosis factor like ligand 1A (TL1A), and TL1A is the only known signaling ligand for DR3, signaling through no other receptors. Preclinical studies showed SL-325 blocked TL1A binding to DR3 more effectively than sequence equivalents of leading TL1A blocking antibodies. The company is currently conducting a single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1 clinical trial for SL-325 in healthy volunteers, which is expected to be completed in the second quarter of 2026. A randomized, placebo-controlled Phase 2 clinical trial evaluating SL-325 in patients with Crohn's Disease (CD) is expected to begin in the third quarter of 2026.